search
Back to results

A Controlled Study of Olanzapine in Children With Autism

Primary Purpose

Autistic Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
olanzapine (Zyprexa)
Placebo
Sponsored by
FDA Office of Orphan Products Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autistic Disorder focused on measuring Autism, Pervasive Developmental Disorder, Treatment, Olanzapine, Antipsychotic

Eligibility Criteria

3 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males and females, Aged between 3 and 12 years. Autistic disorder - DSM-IV criteria. A score of at least moderately impaired on the CGI-Severity item. Clinical judgment that medication treatment for autism is indicated. Exclusion Criteria: Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and PDD, NOS. Psychotic disorder (DSM-IV) (including schizophreniform disorder and schizophrenia). Major depressive disorder (DSM-IV). Bipolar disorder (DSM-IV). History of psychoactive drug in the previous 2 weeks prior to phase 1. A history of treatment with olanzapine for a cumulative period of greater than 2 weeks prior to entering phase 1. Systemic diseases such as cardiac, renal, thyroid diseases, uncontrolled seizure disorder (seizure disorder that is not controlled by anti-epileptic medication - a child who is seizure free for a period of 6 months on a stable dose of antiepileptic drug would be considered controlled), or diabetes mellitus. Children with a known medical cause for autistic disorder. Abnormal fasting blood glucose or history of diabetes. Baseline body mass index (BMI) greater than the 90th percentile for age and gender (CDC growth charts, Kuczmarski et al, 2000) (because of risk of weight gain). Baseline QTc >450 msec. Note: Historically, patients we evaluate do not have QTc values >450. Dyskinesias at baseline (per the criteria of Schooler and Kane, 1982).

Sites / Locations

  • Drexel University College of Medicine c/o Friends Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Treatment with olanzapine

Matching placebo treatment

Outcomes

Primary Outcome Measures

Children's Psychiatric Rating Scale

Secondary Outcome Measures

Clinical Global Impressions
Aberant Behavior Checklist
Treatment Emergent Symptoms Scale
Olanzapine Untoward Effects Checklist
Abnormal Involuntary Movement Scale
Neurological Rating Scale

Full Information

First Posted
April 1, 2003
Last Updated
March 24, 2015
Sponsor
FDA Office of Orphan Products Development
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00057408
Brief Title
A Controlled Study of Olanzapine in Children With Autism
Official Title
A Controlled Study of Olanzapine in Children With Autism
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
May 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
FDA Office of Orphan Products Development
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old. The first six weeks of the study are double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. In the second six weeks all of the patients receive olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autistic Disorder
Keywords
Autism, Pervasive Developmental Disorder, Treatment, Olanzapine, Antipsychotic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Treatment with olanzapine
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Matching placebo treatment
Intervention Type
Drug
Intervention Name(s)
olanzapine (Zyprexa)
Other Intervention Name(s)
Antipsychotic Drug
Intervention Description
Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo controlled
Intervention Description
Matching Placebo
Primary Outcome Measure Information:
Title
Children's Psychiatric Rating Scale
Time Frame
Weekly
Secondary Outcome Measure Information:
Title
Clinical Global Impressions
Time Frame
Weekly
Title
Aberant Behavior Checklist
Time Frame
Weekly
Title
Treatment Emergent Symptoms Scale
Time Frame
Weekly
Title
Olanzapine Untoward Effects Checklist
Time Frame
Weekly
Title
Abnormal Involuntary Movement Scale
Time Frame
Weekly
Title
Neurological Rating Scale
Time Frame
Weekly

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females, Aged between 3 and 12 years. Autistic disorder - DSM-IV criteria. A score of at least moderately impaired on the CGI-Severity item. Clinical judgment that medication treatment for autism is indicated. Exclusion Criteria: Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and PDD, NOS. Psychotic disorder (DSM-IV) (including schizophreniform disorder and schizophrenia). Major depressive disorder (DSM-IV). Bipolar disorder (DSM-IV). History of psychoactive drug in the previous 2 weeks prior to phase 1. A history of treatment with olanzapine for a cumulative period of greater than 2 weeks prior to entering phase 1. Systemic diseases such as cardiac, renal, thyroid diseases, uncontrolled seizure disorder (seizure disorder that is not controlled by anti-epileptic medication - a child who is seizure free for a period of 6 months on a stable dose of antiepileptic drug would be considered controlled), or diabetes mellitus. Children with a known medical cause for autistic disorder. Abnormal fasting blood glucose or history of diabetes. Baseline body mass index (BMI) greater than the 90th percentile for age and gender (CDC growth charts, Kuczmarski et al, 2000) (because of risk of weight gain). Baseline QTc >450 msec. Note: Historically, patients we evaluate do not have QTc values >450. Dyskinesias at baseline (per the criteria of Schooler and Kane, 1982).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard P Malone, MD
Organizational Affiliation
Drexel University College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Drexel University College of Medicine c/o Friends Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19124
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Controlled Study of Olanzapine in Children With Autism

We'll reach out to this number within 24 hrs